When Aakash, a 28-year-old with type-2 diabetes, started taking Mounjaro earlier this year, his life changed dramatically. The drug, a GLP-1 (glucagon-like peptide-1) injection, quickly cut his appetite, forcing him to reimagine his diet. “I immediately feel nausea if I eat over my appetite,” he said.
In just six months, Aakash shed more than 19 kg—but not without effort. He had to reduce portion sizes, prioritize high-protein and high-fibre foods to avoid muscle loss, and completely cut out processed junk. “What I fed myself was still my choice, and that is what had to change by my own sheer will,” he explained.
Aakash’s journey mirrors a much larger shift unfolding across India, where diabetes and obesity drugs such as Mounjaro, Wegovy, and Ozempic are creating ripples far beyond hospitals and pharmacies.
The Science and the Hype Around GLP-1 Drugs
GLP-1 drugs mimic a natural hormone that regulates blood sugar while giving a sense of fullness. Originally designed for diabetics, they’ve become widely popular worldwide for weight loss. In India, Eli Lilly’s Mounjaro launched in March and quickly sold 150,000 units, while Novo Nordisk’s Wegovy followed in June, selling 5,000 units within two months.
But the price remains steep—₹14,000–28,000 a month for Mounjaro and ₹17,000–26,000 for Wegovy. That could change as patents expire, opening the door to cheaper generics. Analysts expect a price crash of up to 80%, which could put these drugs within reach of millions more Indians.
India’s weight-loss drug market, valued at about ₹600 crore in mid-2025, is projected to balloon to over ₹8,000 crore in just 2–3 years.
How Food Habits Are Shifting
The effectiveness of GLP-1 drugs depends not just on injections, but on sustained lifestyle changes. Patients are encouraged to:
- Eat smaller, portion-controlled meals.
- Increase fibre intake for fullness.
- Boost protein consumption to preserve muscle mass.
- Cut back on refined carbs and processed snacks.
This shift is driving demand for healthier packaged foods, from sugar-free biscuits to millet-based snacks. According to Mintel research, 36% of Indian women now prefer biscuits that aid weight loss, and 40% of consumers would choose a salty snack if it had fewer calories.
FMCG Giants Race to Capture the Market
India’s consumer goods companies are quick to sense opportunity:
- Tata Consumer Products has expanded its health-focused portfolio, acquiring millet-based Soulfull (₹155.8 crore), Organic India (₹1,900 crore), and Capital Foods (₹5,100 crore). It is actively developing GLP-1-friendly foods high in protein and fibre.
- ITC Ltd has invested heavily in Yogabar and 24 Mantra Organic, while also launching Right Shift, a nutrition-focused line for people over 40. ITC is doubling down on snacks infused with millets, protein, and fibre.
- Marico entered the healthy snacking space by acquiring a majority stake in True Elements, while Amul rolled out high-protein dairy products like fortified curd and paneer.
- Global parallels: Nestlé in the US has already launched Vital Pursuit, a frozen-meal range designed specifically for GLP-1 users. Indian companies, however, are more cautious about directly targeting this demographic, fearing it could normalize drug use for cosmetic rather than medical reasons.
The Bigger Picture: A Lifestyle Economy in Transition
The rise of GLP-1 drugs isn’t just a pharmaceutical story—it’s a consumer shift. Demand is rising for “better-for-you” products such as baked chips, digestive biscuits, and whole-grain snacks. While still small—healthy variants make up 5–10% of India’s chips market and about 20% of biscuits—experts predict this share will rise steadily over the next decade.
By FY26, India’s packaged food industry is expected to touch ₹4.9 trillion, up from ₹3.2 trillion in FY22. Much of this growth will be shaped by consumers seeking foods that curb hunger, boost nutrition, and complement their medical regimens.
As Suhasini Sampath, co-founder of Yogabar, put it: “We will take consumption away from chocolates, biscuits, and chips. Over time, snacking will get healthier.”
What Lies Ahead
While affordability remains a barrier today, the post-patent landscape promises a surge of generic GLP-1 drugs in India. This will not only make medical weight loss accessible to more people but also accelerate the evolution of the food industry.
Healthy snacking, once a niche, is now poised to become mainstream. The question is not if, but how fast India’s food shelves will adapt to the new wave of consumers who want their snacks to not just taste good, but also keep them fuller, fitter, and healthier.
Feel free to share your experiences and insights in the comments below. Let’s continue the conversation and grow together as a community of traders and analysts.
By sharing this experience and insights, I hope to contribute to the collective knowledge of our professional community, encouraging a culture of strategic thinking and informed decision-making.
As always, thorough research and risk management are crucial. The dynamic nature of financial markets demands vigilance, agility, and a deep understanding of the tools at your disposal. Here’s to profitable trading and navigating the election season with confidence!
Ready to stay ahead of market trends and make informed investment decisions? Follow our page for more insights and updates on the latest in the financial world!
For a free online stock market training by Yogeshwar Vashishtha (M.Tech IIT) this Saturday from 11 am – 1 pm, please sign up with https://pathfinderstrainings.in/training/freetrainings.aspx
Experience profits with my winning algo strategies – get a free one-month trial with ₹15 lakh capital! – https://terminal.algofinders.com/algo-terminal
Disclaimer
This article should not be interpreted as investment advice. For any investment decisions, consult a reputable financial advisor. The author and publisher are not responsible for any losses incurred by investors or traders based on the information provided.